$-0.19
(Market cap
$608 Mln
Revenue (TTM)
$207 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
222.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
129,983,253
5 Years Aggregate
CFO
$-0.91 Mln
EBITDA
$13.81 Mln
Net Profit
$-2.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cytek Biosciences Inc (CTKB)
| -9.1 | 8.8 | 9.5 | 10.9 | -15.5 | -27.4 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Cytek Biosciences Inc (CTKB)
| -22.2 | -28.6 | -10.7 | -37.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cytek Biosciences Inc (CTKB)
|
4.6 | 608.3 | 206.7 | -80.6 | -18.9 | -24.3 | -- | 1.9 |
| 60.9 | 8,018.1 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.2 | |
| 14.2 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 56.0 | 8,696.7 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 176.8 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.9 | 6,577.5 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.1 | 5.0 | |
| 322.7 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 168.3 | 9,947.9 | 785.1 | 41.5 | 9.9 | 2 | 251.8 | 4.9 | |
| 29.0 | 12,153.4 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.9 | 2.4 |
Shareholding Pattern
View DetailsAbout Cytek Biosciences Inc (CTKB)
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora... evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Read more
-
President, CEO & Chairman of the Board
Dr. Wenbin Jiang Ph.D.
-
President, CEO & Chairman of the Board
Dr. Wenbin Jiang Ph.D.
-
Headquarters
Fremont, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cytek Biosciences Inc (CTKB)
What is the current share price of Cytek Biosciences Inc (CTKB) Today?
The share price of Cytek Biosciences Inc (CTKB) is $4.59 (NASDAQ) as of 01-Sep-2026 15:39 EDT. Cytek Biosciences Inc (CTKB) has given a return of -15.47% in the last 3 years.
What is the current PB & PE ratio of Cytek Biosciences Inc (CTKB)?
Since, TTM earnings of Cytek Biosciences Inc (CTKB) is negative, P/E ratio is not available.
The P/B ratio of Cytek Biosciences Inc (CTKB) is 1.86 times as on 28-Aug-2026, a 51 discount to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.73 |
1.89 |
2024 |
-139.29 |
2.12 |
2023 |
-98.13 |
3.03 |
2022 |
543.10 |
3.29 |
2021 |
617.98 |
4.58 |
What is the 52 Week High and Low of Cytek Biosciences Inc (CTKB)?
The 52-week high and low of Cytek Biosciences Inc (CTKB) are Rs 6.18 and Rs 3.28 as of 02-Sep-2026.
What is the market cap of Cytek Biosciences Inc (CTKB)?
Cytek Biosciences Inc (CTKB) has a market capitalisation of $ 608 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cytek Biosciences Inc (CTKB)?
Before investing in Cytek Biosciences Inc (CTKB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.